Patents by Inventor Angela Sutterer
Angela Sutterer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240033239Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: ApplicationFiled: October 5, 2023Publication date: February 1, 2024Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Patent number: 11045438Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: GrantFiled: October 21, 2019Date of Patent: June 29, 2021Assignee: Exela Sterile Medicines LLCInventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Publication number: 20210137869Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: ApplicationFiled: December 31, 2020Publication date: May 13, 2021Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Publication number: 20200289447Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: ApplicationFiled: October 21, 2019Publication date: September 17, 2020Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Publication number: 20200289446Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: ApplicationFiled: October 21, 2019Publication date: September 17, 2020Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Publication number: 20200289448Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: ApplicationFiled: November 7, 2019Publication date: September 17, 2020Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Patent number: 10702490Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: GrantFiled: November 7, 2019Date of Patent: July 7, 2020Assignee: Avadel Legacy Pharmaceuticals, LLCInventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Patent number: 10543186Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: GrantFiled: April 2, 2019Date of Patent: January 28, 2020Assignee: Flamel Ireland LimitedInventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Patent number: 10493051Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.Type: GrantFiled: March 15, 2019Date of Patent: December 3, 2019Assignee: Flamel Ireland LimitedInventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
-
Publication number: 20190216842Abstract: The present invention relates generally to vitamin 12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: ApplicationFiled: March 8, 2019Publication date: July 18, 2019Inventors: Theodore H. FELLER, Angela SUTTERER, Thomas E. FLEMING
-
Patent number: 10335381Abstract: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.Type: GrantFiled: October 13, 2017Date of Patent: July 2, 2019Assignee: University of MississippiInventors: Michael A Repka, Angela Sutterer
-
Patent number: 10251908Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: GrantFiled: June 12, 2015Date of Patent: April 9, 2019Assignee: ENDO PHARMACEUTICALS INC.Inventors: Theodore H. Feller, Angela Sutterer, Thomas E. Fleming
-
Patent number: 10052344Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: GrantFiled: October 8, 2015Date of Patent: August 21, 2018Assignee: ENDO PHARMACEUTICALS INC.Inventors: Theodore H. Feller, Angela Sutterer, Thomas E. Fleming
-
Publication number: 20180036263Abstract: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.Type: ApplicationFiled: October 13, 2017Publication date: February 8, 2018Inventors: Michael A. Repka, Angela Sutterer
-
Patent number: 9801837Abstract: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.Type: GrantFiled: May 8, 2007Date of Patent: October 31, 2017Assignee: The University of MississippiInventors: Michael A. Repka, Hossein Shabany, Angela Sutterer
-
Publication number: 20160022726Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: ApplicationFiled: October 8, 2015Publication date: January 28, 2016Inventors: Theodore H. FELLER, Angela SUTTERER, Thomas E. FLEMING
-
Patent number: 9186374Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: GrantFiled: November 13, 2009Date of Patent: November 17, 2015Assignee: Par Pharmaceutical, Inc.Inventors: Theodore H. Feller, Angela Sutterer, Patrick J. Arnall
-
Publication number: 20150272876Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: ApplicationFiled: June 12, 2015Publication date: October 1, 2015Inventors: Theodore H. FELLER, Angela Sutterer, Thomas E. Fleming
-
Publication number: 20110178048Abstract: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.Type: ApplicationFiled: May 8, 2007Publication date: July 21, 2011Inventors: Michael A. Repka, Hossein Shabany, Angela Sutterer
-
Publication number: 20100210580Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: ApplicationFiled: November 13, 2009Publication date: August 19, 2010Applicant: FLEMING AND COMPANY, PHARMACEUTICALSInventors: Theodore H. Feller, Angela Sutterer, Thomas E. Fleming, Patrick J. Arnall